<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911817</url>
  </required_header>
  <id_info>
    <org_study_id>169</org_study_id>
    <nct_id>NCT03911817</nct_id>
  </id_info>
  <brief_title>Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients</brief_title>
  <official_title>Impact of Midodrine Administration on the Clinical Outcome of Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Assess the impact of midodrine administration on weaning of IV vasopressors

        2. Assess the cost effectiveness of using midodrine in critically ill patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled clinical trial on total 60 critically ill patients
      admitted to critical care medicine department with indication to IV vasopressor due to septic
      shock on admission or during intensive care unit stay and they are randomly assigned to
      either of 2 groups as follows

        1. Group 1(n=30):will receive IV vasopressor infusion only

        2. Group 2(n=30):will receive midodrine in addition to IV vasopressor infusion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2017</start_date>
  <completion_date type="Actual">July 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized controlled clinical trial</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of weaning of IV vasopressor in both groups</measure>
    <time_frame>Starting from date of randomization till stop of IV vasopressor completely or date of death from any cause,whichever came first,assessed up to 30 days</time_frame>
    <description>measure duration needed to completely stop IV vasopressor in both groups and the impact of adding midodrine on that duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>Starting from date of randomization until ICU discharge or date of death from any cause,whichever came first,assessed up to 30 days</time_frame>
    <description>total duration of patient stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ICU discharge after IV vasopressor discontinuation</measure>
    <time_frame>Starting from discontinuation of IV vasopressor until time to ICU discharge or date of death from any cause ,whichever came first,assessed up to 30 days</time_frame>
    <description>measure duration from IV vasopressor stop till ICU discharge or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ICU discharge after midodrine initiation</measure>
    <time_frame>Starting from midodrine initiation until ICU discharge or date of death from any cause,whichever came first,assessed up to 30 days</time_frame>
    <description>measure duration from midodrine start till ICU discharge or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>measure if patient die or discharge from the ICU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>IV vasopressor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will receive IV vasopressor infusion only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midodrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive midodrine in addition to IV vasopressor infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge</description>
    <arm_group_label>Midodrine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (18-80)years

          2. Hypotensive (systolic blood pressure&lt;90mm Hg)and require IV vasopressor for more than
             24 hours

          3. Require IV vasopressor at rate &lt; 8mcg/min and unable to wean for &gt;24 hours

        Exclusion Criteria:

          1. Severe organic heart disease (ejection fraction &lt;30 percent due to higher risk of
             arrythmia)

          2. Bradycardia (HR&lt;50 b/m)due to higher likelihood of symptomatic bradycardia

          3. Chronic kidney disease (serum creatinine &gt;2mg/dl) as midodrine and its active
             metabolites are almost completely execreated in urine

          4. Thyrotoxicosis

          5. Known allergy to midodrine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lamiaa ELwakeel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Critical Care Medicine Department - Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Anstey MH, Wibrow B, Thevathasan T, Roberts B, Chhangani K, Ng PY, Levine A, DiBiasio A, Sarge T, Eikermann M. Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial). BMC Anesthesiol. 2017 Mar 21;17(1):47. doi: 10.1186/s12871-017-0339-x.</citation>
    <PMID>28327122</PMID>
  </reference>
  <reference>
    <citation>Whitson MR, Mo E, Nabi T, Healy L, Koenig S, Narasimhan M, Mayo PH. Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock. Chest. 2016 Jun;149(6):1380-3. doi: 10.1016/j.chest.2016.02.657. Epub 2016 Mar 4.</citation>
    <PMID>26953217</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dina hussein ahmed eladly</investigator_full_name>
    <investigator_title>clinical pharmacist</investigator_title>
  </responsible_party>
  <keyword>Midodrine</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Norepinephrine</keyword>
  <keyword>Weaning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

